Articles

Pharma Pulse 7/31/25: Where Has AI Already Been Successfully Implemented; How Biomarkers Are Transforming Neurology and Oncology Trials

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle details how manufacturers can overcome the data gaps from suppliers and third parties when aiming for sustainability certifications or ESG reporting compliance.

Tackling ESG Data Gaps in Supplier and Third-Party Reporting

A JAMA Network Open study reveals that patients with private insurance can face monthly costs nearing $600 after a cancer diagnosis, highlighting the disparities based on cancer stage and calling for stronger financial support policies.

High Out-of-Pocket Costs Burden Privately Insured Cancer Patients, Study Finds

Pharma Pulse 7/30/25: Growing Excitement Around Biomarkers in Clinical Trials; Emrelis Could Establish AbbVie as a Competitor in MET-High NSCLC Treatment

In the first part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.

How Predictive Maintenance and Localized Distribution Are Shaping Pharma’s Future

In the final part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, discusses the potential repercussions of telehealth companies selling GLP-1s.

Weighing Cost Savings Against Safety and Regulatory Risks

The new deal imposes 15% tariffs on most EU exports, including pharmaceuticals.

United States, European Union Reach Trade Pact

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, dives into the metrics pharma companies can track today in order to measure distribution-related sustainability performance.

Practical Sustainability Metrics for Pharma

Pharma Pulse 7/29/25: Rethinking Oncology Trials with a Statistical Methodology That Puts Patients First; How Can Real World Data and AI Help Solve Issues with Clinical Trials?

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, explains the meaning behind Scope 3 emissions, including why they pose such a challenge for pharma manufacturers.

News